Compare SBFM & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SBFM | BRTX |
|---|---|---|
| Founded | 2006 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Managed Health Care |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3M | 3.7M |
| IPO Year | 2008 | 2015 |
| Metric | SBFM | BRTX |
|---|---|---|
| Price | $0.80 | $2.31 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | 125.0K | ★ 169.5K |
| Earning Date | 04-03-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $36,305,891.00 | $81,000.00 |
| Revenue This Year | $40.47 | $298.39 |
| Revenue Next Year | N/A | $64.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 4.11 | N/A |
| 52 Week Low | $0.25 | $0.14 |
| 52 Week High | $3.05 | $4.10 |
| Indicator | SBFM | BRTX |
|---|---|---|
| Relative Strength Index (RSI) | 28.87 | 56.12 |
| Support Level | $0.27 | $0.22 |
| Resistance Level | $1.26 | $2.93 |
| Average True Range (ATR) | 0.07 | 0.17 |
| MACD | -0.01 | -0.08 |
| Stochastic Oscillator | 5.11 | 2.35 |
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.